论文部分内容阅读
目的探讨血栓通联合依达拉奉治疗急性脑梗死的临床疗效。方法选取无锡市锡山人民医院安镇院区2015年1月—2016年1月收治的急性脑梗死患者50例,根据治疗方法的不同分为对照组(n=13)和观察组(n=37)。患者入院后均完善常规检查及对症治疗,对照组患者给予血栓通治疗,观察组患者在对照组基础上给予依达拉奉治疗,两组患者均持续治疗14 d。比较两组患者治疗前及治疗后10 d血清指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、过氧化氢酯(CAT)]、Barthe I指数评定量表(BI指数)、欧洲卒中临床神经缺损评分量表(ESS)评分及美国国立卫生院神经功能缺损评分量表(NIHSS)评分,并比较两组患者的临床疗效。结果治疗前,两组患者SOD、MDA、CAT比较,差异无统计学意义(P>0.05);治疗后10 d,观察组患者SOD、CAT高于对照组,MDA低于对照组(P<0.05)。治疗前,两组患者BI指数、ESS评分和NIHSS评分比较,差异无统计学意义(P>0.05);治疗后,观察组患者BI指数、ESS评分高于对照组,NIHSS评分低于对照组(P<0.05)。观察组患者治疗总有效率高于对照组(P<0.05)。结论采用血栓通联合依达拉奉治疗急性脑梗死的临床疗效确切,可有效改善患者的神经功能缺损程度,提高日常生活能力,还可加强脑组织的保护作用。
Objective To investigate the clinical efficacy of Xueshuantong combined with edaravone in the treatment of acute cerebral infarction. Methods Fifty patients with acute cerebral infarction from January 2015 to January 2016 in Anzhen Hospital of Wuxi Xishan People’s Hospital were divided into control group (n = 13) and observation group (n = 37) according to different treatment methods ). Patients admitted to the hospital were improved routine examination and symptomatic treatment, the control group of patients given Xueshuantong treatment, the observation group was treated with edaravone on the basis of the control group, two groups of patients were treated for 14 days. The levels of serum SOD, MDA and CAT in the two groups before treatment and 10 days after treatment were compared. The Barthe I index (BI index) European Stroke Clinical Neurological Deficiency Scale (ESS) score and National Institutes of Health neurological deficit scale (NIHSS) score, and compared the clinical efficacy of two groups of patients. Results Before treatment, there was no significant difference in SOD, MDA and CAT between the two groups (P> 0.05). On the 10th day after treatment, the SOD and CAT in the observation group were higher than those in the control group (P <0.05) ). Before treatment, there was no significant difference in BI index, ESS score and NIHSS score between the two groups (P> 0.05). After treatment, BI index and ESS score in observation group were higher than those in control group, NIHSS score was lower than that in control group P <0.05). The total effective rate of observation group was higher than that of control group (P <0.05). Conclusion Xuesaantong combined with edaravone in the treatment of acute cerebral infarction clinical efficacy is exact, can effectively improve the patient’s neurological deficit, improve daily living ability, but also enhance the protective effect of brain tissue.